Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis

Affiliations

• ¹ Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, VIC 3004, Australia.
• ² Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, VIC 3004, Australia; Department of Cardiology B, Oslo University Hospital Ullevål, 0407 Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Norway.
• ³ Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, VIC 3004, Australia; Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, VIC 3068 Australia.
• ⁴ Novartis Pharmaceuticals Corp., Development Franchise - Critical Care, East Hanover, USA.
• ⁵ Novartis Pharma DS&E and Oncology, Drug Safety and Epidemiology, Basel, Switzerland.
• ⁶ Department of Cardiology B, Oslo University Hospital Ullevål, 0407 Oslo, Norway.
• ⁷ Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, VIC 3004, Australia. Electronic address: henry.krum@monash.edu.